Kiniksa Pharmaceuticals' (KNSA) Outperform Rating Reiterated at Wedbush

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report)'s stock had its "outperform" rating reiterated by investment analysts at Wedbush in a research report issued on Monday,RTT News reports. They presently have a $34.00 price objective on the stock. Wedbush's target price would indicate a potential upside of 87.12% from the stock's current price.

A number of other research analysts have also issued reports on the company. JPMorgan Chase & Co. lifted their target price on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an "overweight" rating in a report on Tuesday, November 5th. Evercore ISI lifted their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an "outperform" rating in a report on Wednesday, October 30th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals has a consensus rating of "Buy" and an average target price of $36.60.

Kiniksa Pharmaceuticals Trading Down 8.8 %

NASDAQ:KNSA traded down $1.76 during midday trading on Monday, reaching $18.17. The company had a trading volume of 684,008 shares, compared to its average volume of 492,215. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -129.78 and a beta of 0.29. The stock's fifty day simple moving average is $21.08 and its 200-day simple moving average is $23.28. Kiniksa Pharmaceuticals has a 12-month low of $16.56 and a 12-month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.17). The company had revenue of $112.21 million during the quarter, compared to analysts' expectations of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company's revenue for the quarter was up 67.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.20) earnings per share. As a group, sell-side analysts expect that Kiniksa Pharmaceuticals will post -0.55 EPS for the current year.

Insiders Place Their Bets

In other news, COO Eben Tessari sold 17,000 shares of the business's stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the completion of the sale, the chief operating officer now directly owns 109,975 shares of the company's stock, valued at approximately $2,955,028.25. The trade was a 13.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Mark Ragosa sold 8,969 shares of the business's stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total value of $192,385.05. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares of the company's stock, valued at $492,449.10. The trade was a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 27,092 shares of company stock valued at $673,039 in the last ninety days. Insiders own 54.57% of the company's stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in KNSA. Wellington Management Group LLP acquired a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $1,192,000. Dimensional Fund Advisors LP increased its position in Kiniksa Pharmaceuticals by 31.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company's stock worth $12,398,000 after purchasing an additional 157,741 shares during the period. Segall Bryant & Hamill LLC acquired a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $675,000. Parkman Healthcare Partners LLC increased its position in Kiniksa Pharmaceuticals by 16.7% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company's stock worth $18,874,000 after purchasing an additional 108,102 shares during the period. Finally, Millennium Management LLC increased its position in Kiniksa Pharmaceuticals by 159.8% during the 2nd quarter. Millennium Management LLC now owns 621,948 shares of the company's stock worth $11,612,000 after purchasing an additional 382,539 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.